We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




New Gel Extends Release Half-Life of PEGylated Drugs

By LabMedica International staff writers
Posted on 08 Jul 2015
Print article
Image: Photograph (left) and optical microscopic (right) images of the new hydrogels with polyethylene glycol (PEG) microstructures developed to enable burst-free sustained-release of PEGylated protein drugs such as PEGylated interferon (Photo courtesy of A*STAR’s Institute of Bioengineering and Nanotechnology).
Image: Photograph (left) and optical microscopic (right) images of the new hydrogels with polyethylene glycol (PEG) microstructures developed to enable burst-free sustained-release of PEGylated protein drugs such as PEGylated interferon (Photo courtesy of A*STAR’s Institute of Bioengineering and Nanotechnology).
Researchers have developed a first-of-its-kind hydrogel for more effective long-term drug delivery that would also reduce side-effects and discomfort for patients. Their proof-of-concept study showed effectiveness of the hydrogel with the hepatitis C drug PEGylated-interferon.

The team of researchers, led by Dr. Motoichi Kurisawa, principal research scientist at the Institute of Bioengineering and Nanotechnology (IBN; Singapore) of Singapore’s Agency for Science, Technology and Research (A*STAR), developed a hydrogel that enables burst-free sustained-release of PEGylated protein drugs. “The new gel from IBN prevents premature drug release in the body. This allows for long-term drug delivery and reduces the side effects from frequent drug administration. We hope that our solution can improve the treatment and well-being of patients suffering from chronic diseases such as hepatitis C,” said Prof. Jackie Y. Ying, IBN executive director.

Standard treatment for chronic hepatitis C infections includes weekly injection of PEGylated interferon. The frequent injections increases patient discomfort, is time-consuming, and can cause depression and fatigue. It has not been possible to use hydrogels to deliver drugs with long-term efficacy because controlling the drug release rate is difficult. Most hydrogels have a porous structure that causes the encapsulated drugs to leak prematurely and be eliminated rapidly from the body.

The team found a way to regulate the release rate and duration by creating a gel with 3-D microscopic structures of the polymer polyethylene glycol (PEG). The microstructures function like “reservoirs” for PEGylated drugs because of the presence of PEG on the drug. This property prevents premature leaking. The drugs will also flow in and out of the many reservoirs in the gel before being released into the body. This property helps slow the drug diffusion rate. Duration of drug action can also be controlled by changing the size of the reservoir microstructures.

The study showed that a one-time administration of the hydrogel containing the PEGylated interferon was as effective as 8 injections of the medication alone, and that drug effect can last up to 2 months. The hydrogels will degrade naturally and be eliminated from the body once the drugs are fully released.

“Our hydrogels can significantly extend the half-life of hepatitis C drugs by up to 10 times longer than current treatment,” said Dr. Kurisawa, “This work improves the therapeutic efficiency of the drugs, while reducing the need for frequent injections.” “I believe that our method can pave the way for more effective and safe treatment of hepatitis C. We are also testing the microstructured gel for the treatment of other chronic diseases besides hepatitis C,” added Dr Kurisawa.

The study, by Bae KH et al., was published online ahead of print June 11, 2015, in the journal Biomaterials.

Related Links:

Institute of Bioengineering and Nanotechnology
Singapore Agency for Science, Technology and Research (A*STAR) 


Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Unit-Dose Packaging solution
HLX
New
Quantitative Immunoassay Analyzer
AS050
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.